# ABIVAX Société Anonyme (ABVX)

> Source: Nexqual · https://nexqual.com/ABVX · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, ABIVAX Société Anonyme (ABVX), nexqual.com/ABVX" · informational, not investment advice.

**Price:** USD 90.23 (-3.49% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 93.49 · day 88.15–93.98 · 52w 69.81–148.83 · market cap $7.87B · NGM

## Key facts
- 1 of 80 tracked superinvestors hold ABVX (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 1.67 on a 1–5 scale) (12 analysts), mean target USD 163.58 (range 142–181).
- Total return with dividends: 1Y -0.3% vs S&P 500 +14.9%; 5Y +987.1% vs S&P 500 +80.3%.
- Next earnings: 2026-09-21, EPS estimate USD -0.86, revenue estimate $676K.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold ABVX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Lee Ainslie | Maverick Capital | 0.05% | $5.3M | New position |

## Analysts
Consensus Buy (mean 1.67 on a 1–5 scale), 12 analysts; mean target USD 163.58 (low 142, high 181).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | Wedbush | Target lowered | Neutral | $118 → $96 |
| 2026-10-20 | Guggenheim | Reiterated | Buy | $175 |
| 2026-09-22 | Truist Securities | Target lowered | Buy | $155 → $151 |
| 2026-09-22 | Wedbush | Target lowered | Neutral | $140 → $118 |
| 2026-09-22 | Barclays | Maintained | Overweight | $148 |
| 2026-09-10 | Goldman Sachs | Initiated | Buy | $155 |
| 2026-09-05 | BTIG | Reiterated | Buy | $175 |
| 2026-07-09 | Piper Sandler | Target raised | Overweight | $165 → $175 |
| 2026-07-02 | Truist Securities | Target raised | Buy | $135 → $155 |
| 2026-07-01 | Citizens | Reiterated | Market Outperform | $187 |
| 2026-06-30 | Jefferies | Upgrade | Hold → Buy | $108 → $158 |
| 2026-06-30 | Leerink Partners | Target raised | Outperform | $140 → $148 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2023-10-16) |
|---|---|---|
| Total return | -0.3% | +987.1% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -0.3% | +120.4% |
| Volatility (annualized) | 91.1% | 127.8% |
| Max drawdown | -50.1% (Dec 2025→Jun 2026) | -66.3% (Apr 2024→Mar 2025) |

## Peers (Biotechnology)
TGTX (TG Therapeutics, Inc.) USD 53.16 -0.08% · AXSM (Axsome Therapeutics, Inc.) USD 156.07 -0.15% · ARWR (Arrowhead Pharmaceuticals, Inc.) USD 58.36 -0.82% · SYRE (Spyre Therapeutics, Inc.) USD 92.33 -0.67% · CYTK (Cytokinetics, Incorporated) USD 62.33 -0.84% · PTGX (Protagonist Therapeutics, Inc.) USD 139.53 +1.05%

## More
Full page: https://nexqual.com/ABVX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.86 | $-0.67 | +27.4% | $676,440 | 4 |
| Next quarter (ends 2026-12-31) | $-0.89 | $-0.77 | +15.9% | $686,030 | 4 |
| Current fiscal year (ends 2026-12-31) | $-4.17 | $-3.62 | +15.1% | $4.0M | 7 |
| Next fiscal year (ends 2027-12-31) | $-3.84 | $-3.24 | +18.5% | $71.9M | 7 |